Related Experiment Video
Updated: Jul 20, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Inhibitory effects of indirubin-3'-monoxime against human osteosarcoma
Yi Zhang1, Lu Song2, Jiazhen Li1
1Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Indirubin is widely used as the active component of "Dangui Luhui Wan" in ancient China. However, its effects against the osteosarcoma (OS), the most common primary malignancy, are still unknown. In our present study, we investigated the effects of the Indirubin-3'-monoxime (I3M), a derivative of indirubin with better water solubility, against the OS cells. We found I3M inhibited OS cell proliferation in a dose-dependent manner. Flow cytometry assays showed that I3M could not only induce OS cell apoptosis in a time- and dose-dependent manner but also regulate the cell cycle distribution. Additionally, we demonstrated that several Bcl-2 family members, cyclin-dependent kinases (CDKs) and cyclins contributed to this process. Furthermore, out data verified that I3M suppressed OS cell migration and invasion by decreasing MMP-2 and MMP-9 levels. Moreover, survivin and focal adhesion kinase (FAK) might play important roles in the anti-OS effects of I3M. The administration of I3M also inhibited the OS cell growth in mice. Taken together, our results indicated the inhibitory effects of I3M against human OS and thus might be an efficient candidate for OS chemotherapy.
Insights
Indirubin-3'-monoxime (I3M) effectively inhibits osteosarcoma (OS) cell growth, induces apoptosis, and suppresses migration. This indirubin derivative shows promise as a potential chemotherapy agent for osteosarcoma treatment.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Osteosarcoma (OS) is a primary bone malignancy with limited treatment options.
- Indirubin, a traditional Chinese medicine component, has shown therapeutic potential, but its effects on OS are unexplored.
- Indirubin-3 omino (I3M), a water-soluble derivative, was investigated for anti-OS activity.
Purpose of the Study:
- To evaluate the efficacy of Indirubin-3 omino (I3M) against human osteosarcoma (OS) cells.
- To elucidate the mechanisms underlying I3M's anti-cancer effects in OS.
Main Methods:
- In vitro studies using OS cell lines to assess proliferation, apoptosis, and cell cycle.
- Analysis of key molecular targets including Bcl-2 family members, CDKs, cyclins, MMP-2, MMP-9, survivin, and FAK.
- In vivo studies involving tumor xenografts in mice to evaluate I3M's therapeutic effect.
Main Results:
- I3M demonstrated dose-dependent inhibition of OS cell proliferation and induction of apoptosis.
- I3M regulated OS cell cycle distribution and modulated the expression of apoptosis-related proteins and cell cycle regulators.
- I3M suppressed OS cell migration and invasion by reducing MMP-2 and MMP-9 levels, with potential roles for survivin and FAK.
- In vivo administration of I3M inhibited OS tumor growth in mice.
Conclusions:
- Indirubin-3 omino (I3M) exhibits significant inhibitory effects against human osteosarcoma.
- I3M demonstrates potential as a novel therapeutic candidate for osteosarcoma chemotherapy.
